How has Zevra Therapeutics, Inc.'s operating lease liabilities changed year-over-year?

Zevra Therapeutics, Inc.'s operating lease liabilities increased by 35.3% year-over-year, from -$190K to -$123K.

What is the long-term trend for Zevra Therapeutics, Inc.'s operating lease liabilities?

Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s operating lease liabilities has grown at a 27.5% compound annual growth rate (CAGR), from -$326K to -$675K.

Zevra Therapeutics, Inc. ZVRA Operating lease liabilities

Operating lease liabilities at other companies

XER

Xeris Biopharma Holdings, Inc.XERS

——

Theravance BiopharmaTBPH

——

PVL

Palvella TherapeuticsPVLA

——

Arrowhead ResearchARWR

——

Catalyst PharmaceuticalCPRX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$773.23M+58.2%

Enterprise value$678.78M+32.5%

P/E6.2×—

P/S6.3×-5.7×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s operating lease liabilities?: Zevra Therapeutics, Inc. (ZVRA) reported operating lease liabilities of -$123K in Q1 2026.
How has Zevra Therapeutics, Inc.'s operating lease liabilities changed year-over-year?: Zevra Therapeutics, Inc.'s operating lease liabilities increased by 35.3% year-over-year, from -$190K to -$123K.
What is the long-term trend for Zevra Therapeutics, Inc.'s operating lease liabilities?: Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s operating lease liabilities has grown at a 27.5% compound annual growth rate (CAGR), from -$326K to -$675K.